Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 18 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Pharvaris N.V. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 36
- +15 vs. Q3 2023
- Shares held
- 40.7M
- +11.7M (+40.2%) vs. Q3 2023
- Total value
- $1.14B
- +$536.3M (+88.4%) vs. Q3 2023
- New holders
- 18
- 12 more added
- Sold out
- 3
- 4 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 125 | $2.23B |
| Q1 2026 | 110 | $1.67B |
| Q4 2025 | 106 | $1.64B |
| Q3 2025 | 83 | $1.44B |
| Q2 2025 | 60 | $792.7M |
| Q1 2025 | 52 | $705.5M |
| Q4 2024 | 54 | $855.8M |
| Q3 2024 | 51 | $834.2M |
| Q2 2024 | 36 | $808.6M |
| Q1 2024 | 35 | $980.5M |
| Q4 2023 | 36 | $1.14B |
| Q3 2023 | 21 | $606.6M |
| Q2 2023 | 21 | $441.6M |
| Q1 2023 | 21 | $173.9M |
| Q4 2022 | 25 | $239.6M |
| Q3 2022 | 21 | $173.6M |
| Q2 2022 | 20 | $494.0M |
| Q1 2022 | 22 | $397.1M |
| Q4 2021 | 22 | $321.1M |
| Q3 2021 | 25 | $380.3M |
| Q2 2021 | 28 | $406.3M |
| Q1 2021 | 33 | $616.5M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Pharvaris N.V.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Piper Sandler & Co. | 181 | $5.08K | 0.00% | +181 | New |
| JPMorgan Chase & Co | 190 | $5.33K | 0.00% | +190 | New |
| Quarry LP | 750 | $21.0K | 0.01% | +750 | New |
| BlackRock Inc. | 2,268 | $63.6K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 8,198 | $230.0K | 0.00% | +8,198 | New |
| Goldman Sachs Group Inc | 8,549 | $239.8K | 0.00% | +8,549 | New |
| Schonfeld Strategic Advisors LLC | 12,400 | $347.8K | 0.00% | +500+4.2% | Added |
| UBS Oconnor LLC | 18,000 | $504.9K | 0.02% | +18,000 | New |
| Geode Capital Management, LLC | 21,595 | $605.7K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 22,488 | $630.8K | 0.00% | −11,209−33.3% | Reduced |
| Qube Research & Technologies Ltd | 32,318 | $906.5K | 0.00% | +29,739+1,153.1% | Added |
| Manufacturers Life Insurance Company, The | 55,078 | $1.54M | 0.00% | +55,078 | New |
| Marshall Wace, LLP | 60,124 | $1.69M | 0.00% | +60,124 | New |
| Hudson Bay Capital Management LP | 70,134 | $1.97M | 0.02% | +31,241+80.3% | Added |
| Walleye Capital LLC | 77,870 | $2.18M | 0.03% | −3,147−3.9% | Reduced |
| Blackstone Group Inc. | 100,000 | $2.81M | 0.01% | +100,000 | New |
| Citadel Advisors LLC | 141,458 | $3.97M | 0.00% | +141,458 | New |
| Millennium Management LLC | 188,516 | $5.29M | 0.01% | +188,516 | New |
| Soleus Capital Management, L.P. | 217,396 | $6.10M | 0.68% | −126,579−36.8% | Reduced |
| Sphera Funds Management Ltd. | 245,000 | $6.87M | 1.28% | +245,000 | New |
| Vivo Capital, LLC | 285,000 | $7.99M | 0.65% | +285,000 | New |
| Sofinnova Investments, Inc. | 510,441 | $14.3M | 0.80% | +510,441 | New |
| 5AM Venture Management, LLC | 797,600 | $22.4M | 5.93% | +210,000+35.7% | Added |
| Commodore Capital LP | 800,000 | $22.4M | 1.96% | +800,000 | New |
| Deerfield Management Company, L.P. (Series C) | 812,236 | $22.8M | 0.42% | +812,236 | New |
| Price T Rowe Associates Inc | 842,698 | $23.6M | 0.00% | +842,698 | New |
| EcoR1 Capital, LLC | 900,000 | $25.2M | 0.66% | +900,000 | New |
| Novo Holdings A/S | 1,539,325 | $43.2M | 2.89% | +210,000+15.8% | Added |
| Cormorant Asset Management, LP | 1,711,460 | $48.0M | 2.30% | +350,000+25.7% | Added |
| VR Adviser, LLC | 3,395,606 | $95.2M | 6.53% | +1,832,093+117.2% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,656,923 | $102.6M | 0.38% | +425,000+13.2% | Added |
| Bain Capital Life Sciences Investors, LLC | 3,904,319 | $109.5M | 10.50% | −880,355−18.4% | Reduced |
| Foresite Capital Management IV, LLC | 4,038,842 | $113.3M | 57.25% | +295,392+7.9% | Added |
| venBio Partners LLC | 4,919,504 | $138.0M | 20.68% | +654,832+15.4% | Added |
| FMR LLC | 5,192,984 | $145.7M | 0.01% | +1,985,420+61.9% | Added |
| General Atlantic LLC | 6,156,252 | $172.7M | 2.48% | +1,750,000+39.7% | Added |
| Foresite Capital Management V, LLC | 0 | $0 | 0.00% | −33,142−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −17,553−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −50−100.0% | Sold out |